Highlights and Quick Summary
- Employees for the quarter ending December 30, 2020 was $55 (a 120.0% increase compared to previous quarter)
- Annual Employees for 2020 was $55 (a 120.0% increase from previous year)
- Annual Employees for 2019 was $25 (a 56.25% increase from previous year)
Visit stockrow.com/PHAT
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Employees of Phathom Pharmaceuticals, Inc.
Most recent Employeesof PHAT including historical data for past 10 years.Interactive Chart of Employees of Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. Employees for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2020 | – | – | – | $0.0 | $0.0 |
| 2019 | – | – | – | $0.0 | $0.0 |
| 2018 | – | – | – | – | $0.0 |
Business Profile of Phathom Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.